Home › Funds › Artia Global Partners LP › DRUG
Artia Global Partners LP position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
Artia Global Partners LP reported holding 38,407 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.39% of its reported portfolio and ranking #41 among its reported holdings. Artia Global Partners LP has disclosed DRUG holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's DRUG position evolved
Artia Global Partners LP first disclosed a stake in DRUG in Q4 2025 at 33,407 shares (US$2.6M). The position peaked in Q1 2026 at 38,407 shares, worth US$2.8M. Across 4 filings, Artia Global Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 38,407 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 33.41K | $2.61M | New |
| Q1 2026 | 38.41K | $2.80M | Add |
| Q2 2026 | 38.41K | $2.70M | Hold |
| Q3 2026 | 38.41K | $1.91M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 64 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$63.2M), Vestal Point Capital, LP (US$38.3M), BRAIDWELL LP (US$34.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Cormorant Asset Management, LP 900.00K sh · $63.18M · Q2 2026
- Vestal Point Capital, LP 545.00K sh · $38.26M · Q2 2026
- BRAIDWELL LP 483.82K sh · $33.96M · Q2 2026
- Vivo Capital, LLC 417.88K sh · $20.82M · Q3 2026
- MPM BioImpact LLC 202.11K sh · $14.19M · Q2 2026
- GREAT POINT PARTNERS LLC 109.60K sh · $7.69M · Q2 2026
- Ikarian Capital, LLC 88.95K sh · $6.24M · Q2 2026
- B Group, Inc. 95.00K sh · $4.73M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 93.15K sh · $4.64M · Q3 2026
- Sio Capital Management, LLC 75.15K sh · $3.74M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 48.05K sh · $2.39M · Q3 2026
- KVP Capital Advisors, LP 31.81K sh · $1.58M · Q3 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held DRUG?
Artia Global Partners LP has disclosed DRUG holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Artia Global Partners LP's current position in DRUG?
As of Q3 2026, Artia Global Partners LP holds 38.41K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $1.91M, representing 0.39% of its reported portfolio and ranking #41.
Has Artia Global Partners LP been buying or selling DRUG?
In the latest 13F filing (Q3 2026), Artia Global Partners LP held unchanged its position in DRUG. The position peaked in Q1 2026 at 38.41K shares.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vestal Point Capital, LP, BRAIDWELL LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.